Effectiveness of Granulocyte Transfusions in Neutropenic Adult Oncology Patients: A Comprehensive Review of the Literature
Asha Demla, MS, RN, AGPCNP-BC, Lydia T. Madsen, PhD, RN, AOCNS®, and Joyce Dains, DrPH, JD, RN, FNP-BC, DPNAP, FAANP
The University of Texas MD Anderson Cancer Center, Houston, Texas
Authors’ disclosures of potential conflicts of interest are found at the end of this article.
Asha Demla, MS, RN, AGPCNP-BC, 1515 Holcombe Blvd, Unit 0456, Houston, TX 77030. E-mail: email@example.com
J Adv Pract Oncol 2016;7:410–417 |
doi: 10.6004/jadpro.2016.7.4.4 |
© 2016 Harborside Press®
Among patients with cancer, many factors can cause severe and persistent neutropenia, leading to increased morbidity and mortality. For patients with neutrophil deficiency, replacement with granulocyte transfusion (GTX) seems a rational approach. However, existing data on the efficacy of GTX have been inconclusive, and such adverse effects as respiratory distress and death indicate the need for further investigation into its efficacy. The purpose of this literature review was to address the question, “Are granulocyte transfusions effective in the management of adult oncology patients with neutropenia?” The focus was on adequate dosing, optimal timing of initiation, and adverse effects. Implications for practice for the provider and the niche population of neutropenic adult oncology patients that might benefit from GTX are presented.
For access to the full length article, please sign in